Abstract: There is described an aqueous, foamable composition delivered from a foaming device for conditioning, lightening and highlighting hair which comprises: (i) a conditioning agent, (ii) a peroxygen compound, (iii) an acid, and (iv) a foaming agent; said composition having a pH of 5 or less. There is also described a method for conditioning lightening and highlighting hair which comprises treating said hair with a composition of the invention.

Abstract: A pharmaceutical tablet comprising a core and a film coating wherein the core comprises an NSAID and the film coating comprises a polymer and misoprostol.

Abstract: The present invention is directed to improved oral dosage forms that are significantly easier to swallow. In accordance with the present invention, the oral dosage forms are configured to have relatively greater weight and/or density to effect partial or total submergence in the liquid with which the oral dosage form is taken. In one embodiment, a filler is added to the ingredients of the oral dosage form. In another embodiment, a filler is added to the medium of the oral dosage form. In a further embodiment, a filler is added to the exterior of the oral dosage form. In another embodiment, a relatively heavier, denser or larger amount of ingredient is used to formulate the oral dosage form. In yet a further embodiment, a binder is used to increase the weight and/or density of the oral dosage form. In yet another embodiment, a combination comprising a binder and a relatively heavier, denser or larger amount of ingredient is used to formulate the oral dosage form.

Abstract: An aqueous dispersion for the production of binders or coatings for solid oral drugs having a water content of 90-40 wt. % and a solids portion of 10-60 wt. %, whereby said solids portion is composed of: (A) 10-99 wt. % of a polymer mixture consisting of: (a) 75-99 wt. % of a polymethacrylate copolymer consisting of up to 98-85 wt. % of alkyl (meth)acrylate monomers with C1-C4 alkyl residues and up to 2-15 wt. % of alkyl (meth)acrylate monomers with a quaternary ammonium group in the alkyl residue, and (b) 25-1 wt. % of an alkali salt of carboxymethylcellulose having a weight average molecular weight of less than 150,000, and (B) 90-1 wt. % of at least one substance normally added to pharmaceutical formulations.

Abstract: The invention relates to a method of making a solid product in a form capable of being handled based on hydrophobic mineral powder such as talcum or mica powder, in particular for cosmetic or hygienic use. This process is characterized in that a hydrophobic mineral powder, particularly based on talcum or mica, is impregnated using a volatile liquid binder in proportions by weight such that the proportion of volatile liquid binder is at least equal to 5% and the proportion of mineral powder at least equal to 80%, and in that the resulting impregnated powder is pressed so as to shape it and to provide it with cohesion ensuring the rigidity of the product. The solid product obtained can take the form of a stick (7) that can be used to ensure a deposit of talcum or mica by contact.

Abstract: A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35° C. to about 65° C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40° C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.

Abstract: The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation.

Abstract: Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

Abstract: A protective glove includes a coating of dehydrated material on its inside surface. The dehydrated material, in contact with perspiration from a hand wearing the glove, soothes the hand. Some methods of placing the coating onto the inside surface of the glove include spraying or dipping with a solution that includes Aloe Vera.

Abstract: A method for providing nutraceutical or phytoceutical benefits to a mammal, particularly a human, using cherry derivatives is described. A method for inhibiting oxidation in a living biological material is also described. A composition of anthocyanins, bioflavonoids, phenolics or mixtures thereof from cherries is used in the methods.

Abstract: A packaged effervescent product is provided which includes a sachet surrounded by an outer package film sealing the sachet against water vapor transmission. The sachet is a cosmetic article which includes an effervescent cleansing composition of an acid material such as citric add and an alkaline material such as sodium bicarbonate. The composition is held within the sealed sachet or pouch. At least one wall of the pouch is water permeable. The outer package film is formed of a material which must have a breathability for carbon dioxide. Any carbon dioxide generated during storage is thereby allowed to slowly diffuse into the atmosphere while still minimizing the amount of water which may enter the package.

Abstract: A highly safe bone resorption suppressing agents, which can be used as medicines or admixed to food products or feeds, is produced. Milk-derived basic cystatins and/or milk-derived basic cystatin decomposition products prepared from milk are made into bone resorption suppressing agents, or admixed to drinks, food products and feeds.

Abstract: A therapeutic pad comprises a spinel powder having the formula of AB2O4 which emits 3-18 or 3-30 micron wave length depending the composition of the spinel for treatment of pain. A novel method for treatment of pain by placing the said pad with the spinel powder over the painful area.

Abstract: A composite material suitable for external and/or internal association with a living body comprising: a first component having a surface area greater than approximately 10 M2/gm; and a first beneficial agent associated with at least a portion of the high surface area of the first component, wherein the first component is fabricated from a material having a hardness greater than the hardness of the first beneficial agent.

Abstract: Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant.

Abstract: A masking agent for pharmaceutical tastes comprises a mixture of a sapid agent and an enhancer, in the form of an intimate mixture. The sapid agent/enhancer distribution is substantially homogeneous and non-statistical. The proportion of sapid agent relative to the enhancer is substantially constant and equal in all powder particles. The masking agent can have a grain size comprised between 10 and 100 &mgr;m, with a Gaussian distribution. The proportion of sapid agent/enhancer is comprised between 97/3 and 90/10, expressed in parts by weight. The sapid agent comprises a sweetener selected from the group comprising sodium saccharinates, calcium saccharinates, saccharine, aspartyl-phenylalanine, acesulfam, cyclamates, stevioside, and mixtures thereof; and the enhancer is selected from the group comprising thaumatin, neohesperidin dihydrochalcone (NHDC), glycyrrhizin, and mixtures thereof. A method of producing a masking agent is also disclosed.

Abstract: The invention concerns an aqueous solution capable of being injected by perinodular delivery or inhaled for use in the treatment of degenerative or autoimmune diseases or as immunomodulatory agent. Said solution is prepared by reacting camphor on ammonium hydroxide. The resulting product is then suspended in a saline solution. Said preparation having a basic pH is then neutralized with nitric acid. The resulting aqueous solution has pharmacological properties since it is an analogue of human cytokines, which makes it useful for treating degenerative or autoimmune diseases and/or as an immunomodulatory agent.

Abstract: A method of preparing drug particles of a substance which are susceptible to degradation by the use of a fluid gas technique.

Abstract: The present invention relates to a quick disintegrating tablet in buccal cavity, comprising: a mixture, comprising a drug, a sugar (A), and an amorphous sugar (B), and after it is forming a tablet, it is humidified and dried. In particularly, the present invention relates to a quick disintegrating tablet in buccal cavity comprising: a mixture; comprising a drug, a sugar (A), and an amorphous sugar (B) which an amorphous-forming sugar in crystalline state is dissolved in a medicinally permitted solvent, the amorphous sugar is obtained from this solution by removing the solvent, and after it is forming a tablet, and it is humidified and dried. The tablet in the present invention is to provide stability against moisture at preserved, because the amorphous sugar changed to the crystalline state in a nonreversible reaction after it is humidified and dried in a manufacturing process.

Abstract: Celecoxib is provided in a porous matrix form wherein the dissolution rate of the drug is enhanced when the matrix is contacted with an aqueous medium. The porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of celecoxib having a mean diameter between about 0.01 and 5 &mgr;m and a total surface area greater than about 0.5 m2/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL. The porous celecoxib matrices preferably are made using a process that includes (i) dissolving celecoxib in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of celecoxib.